Forbion European Acquisition Corp.

Forbion European Acquisition Corp. (Nasdaq: FRBN) is a blank-check company sponsored by Forbion, a Netherlands-based venture capital firm specializing in life sciences and biopharmaceutical investment across Europe. The SPAC completed its initial public offering in 2021, targeting acquisition opportunities in the European healthcare and life sciences sector — an area where sponsor Forbion brings deep domain expertise through its long-running venture funds. In October 2023, the company filed a DEFA14A with the Securities and Exchange Commission, supplementing previously distributed proxy materials in connection with a pending shareholder vote. For complete filing history, deal status, and investor data on FRBN, create a free account at SpacDesk.